These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23280075)

  • 21. Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A.
    Waiser J; Schneider M; Eljazyfer S; Slowinski T; Glander P; Einecke G; Budde K; Neumayer HH; Böhler T
    Clin Immunol; 2006 Apr; 119(1):59-66. PubMed ID: 16451828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.
    Han F; Wu J; Huang H; Zhang X; He Q; Wang Y; Wang S; Wang H; Chen J
    Exp Clin Transplant; 2011 Feb; 9(1):42-9. PubMed ID: 21605022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S; Liu Y; Wang L; Meng QH
    Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
    Bakker RC; Hollander AA; Mallat MJ; Bruijn JA; Paul LC; de Fijter JW
    Kidney Int; 2003 Sep; 64(3):1027-34. PubMed ID: 12911553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transforming growth factor-beta1 gene expression and cyclosporine A-induced gingival overgrowth: a pilot study.
    Radwan-Oczko M; Boratyńska M; Zietek M; Dobosz T
    J Clin Periodontol; 2008 May; 35(5):371-8. PubMed ID: 18355347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential protocol biopsies from renal transplant recipients show an increasing expression of active TGF beta.
    Jain S; Mohamed MA; Sandford R; Furness PN; Nicholson ML; Talbot D
    Transpl Int; 2002 Dec; 15(12):630-4. PubMed ID: 12478410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
    Rintala JM; Savikko J; Rintala SE; von Willebrand E
    Transplant Proc; 2006 Dec; 38(10):3239-40. PubMed ID: 17175234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients.
    Bertoni E; Larti A; Rosso G; Zanazzi M; Di Maria L; Salvadori M
    J Nephrol; 2011; 24(5):613-8. PubMed ID: 21240873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of renin-angiotensin system in the chronic allograft nephropathy: an immunohistochemical study.
    Viero RM; da Silva MG; dos Santos DC; de Carvalho MF; de Andrade LG
    Ren Fail; 2015 Jun; 37(5):827-34. PubMed ID: 25782922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modifying cyclosporine associated renal allograft dysfunction.
    Mohapatra N; Vanikar AV; Patel RD; Trivedi HL
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):770-4. PubMed ID: 19736471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine single nucleotide polymorphisms and intrarenal gene expression in chronic allograft nephropathy in children.
    Melk A; Henne T; Kollmar T; Strehlau J; Latta K; Offner G; Jhangri GS; Ehrich JH; Von Schnakenburg C
    Kidney Int; 2003 Jul; 64(1):314-20. PubMed ID: 12787424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy.
    Campistol JM; Iñigo P; Jimenez W; Lario S; Clesca PH; Oppenheimer F; Rivera F
    Kidney Int; 1999 Aug; 56(2):714-9. PubMed ID: 10432413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year.
    Benigni A; Bruzzi I; Mister M; Azzollini N; Gaspari F; Perico N; Gotti E; Bertani T; Remuzzi G
    Kidney Int; 1999 Feb; 55(2):674-85. PubMed ID: 9987092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
    Nainani N; Patel N; Tahir N; Kumar R; Weber-Shrikant E; Gundroo AA; Murray BM; Tornatore KM; Blessios GA; Venuto RC
    Nephrol Dial Transplant; 2012 May; 27(5):2077-83. PubMed ID: 22058172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of losartan on slowing progression of chronic allograft nephropathy.
    Wang PX; Fan MQ; Huang CB; Feng JY; Xiao Y; Fang ZQ; Zhang YP
    Chin Med Sci J; 2005 Dec; 20(4):231-6. PubMed ID: 16422249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine microemulsion formulation (sigmasporin microral) effect as first-line immunosuppressant on renal functions at 3 years.
    Al Wakeel J; Shaheen FA; Al Alfi A; Abbas Fagir EH; Iman A; Nampoory MR; Al Mousawi MS; Said T; Abou Zeinab H; Shaker DS; Ghaedi BB
    Transplant Proc; 2012 Jan; 44(1):94-100. PubMed ID: 22310589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
    Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
    Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.